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Glycemic Control Patterns and Kidney Disease
Progression among Primary Care Patients with
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Doyle M. Cummings, PharmD, Lars C. Larsen, MD, Lisa Doherty, MD, MPH,
C. Suzanne Lea, PhD, and Don Holbert, PhD
Background: Reducing glycosylated hemoglobin (HbA1c) to near or less than 7% in patients with diabe-
tes is associated with diminished microvascular complications, but this level is not consistently
achieved. The purpose of this study was to examine the relationship between fluctuations in HbA1c and
changes in estimated glomerular filtration rate (eGFR) and estimated stage of chronic kidney disease
(CKD) in an academic primary care practice.
Methods: We analyzed data from 791 diabetic primary care patients (25% white; 75% African Ameri-
can) enrolled between 1998 to 2002 and followed through 2008 (mean follow-up, 7.6 1.9 years). We
calculated baseline and final follow-up eGFR using the Modification of Diet in Renal Disease equation.
We examined the relationship between fluctuations in HbA1c and changes in eGFR and stage of CKD
using multivariable linear and logistic regression models that controlled for demographic and clinical
variables associated with CKD progression.
Results: From baseline to follow-up, mean eGFR in African Americans declined to a greater extent
and more rapidly than in whites. Age, mean systolic blood pressure, initial HbA1c, initial eGFR, and
number of HbA1c values (all P < .01) were significant predictors of change in eGFR. Among HbA1c fluc-
tuation measures, the strongest predictor of change in eGFR was the proportion of HbA1c values>7%
(P  .02); however, this contributed little to explaining model variance.
Conclusion: These data suggest that traditional demographic and clinical risk factors remain signifi-
cantly associated with changes in eGFR and that the pattern of variability in HbA1c is only modestly im-
portant in contributing to changes in eGFR among African-American and white diabetic patients in pri-
mary care.(J Am Board Fam Med 2011;24:391–398.)
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Prospective clinical trials have demonstrated that
improvements in glycemic control, particularly
early in treatment, are associated with reductions in
the incidence of microvascular complications, in-
cluding chronic kidney disease (CKD).1–9 Notably,
the Diabetes Control and Complications Trial
(DCCT) showed a signiﬁcant relationship between
reduction in glycosylated hemoglobin (HbA1c) lev-
els and the risk of microvascular complications in-
cluding CKD.1,2,9 Similar results were evident in
the United Kingdom Prospective Diabetes
Study,3,6 the Atherosclerosis Risk in Communi-
ties7 study, and very recently in the Action to
Control Cardiovascular Risk in Diabetes trial,8
with more profound hyperglycemia being associ-
ated with a greater risk of CKD. There seemed to
be no threshold value of HbA1c above or below
which complications were not increased or de-
creased, suggesting a continuous relationship be-
tween HbA1c and complications across a wide
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range of values. Long-term follow-up of patients
in the DCCT and United Kingdom Prospective
Diabetes studies demonstrated that glycemic
control that improved early and was maintained
for the study duration, even when lost at the end
of the randomized trial study period, was associ-
ated with a reduction in the incidence of CKD
after 10 years of follow-up.2,4 Furthermore, in a
re-analysis of DCCT follow-up data, Lachin et
al9 concluded that glycemic control, as measured
by HbA1c, explained virtually all the difference
in the risk of complications between intensive
and conventional treatment groups. These ﬁnd-
ings suggest that the timing, magnitude, and du-
ration of improvement in glycemic control
among diabetic patients are important in the pro-
gression to CKD. In most prospective clinical
trials evaluating diabetes outcomes such as the
onset or progression of CKD, 2 groups with
differing target levels of glycemic control (ie,
HbA1c) have been compared (eg, intensive treat-
ment vs usual care).8 However, for longer-term
studies, single measures or beginning and fol-
low-up levels of HbA1c may inadequately char-
acterize the pattern of glycemic control over the
study period. In routine outpatient practice many
diabetic patients do not consistently achieve the
recommended level of glycemic control as de-
ﬁned by the American Diabetes Association.10
Large intra- and interindividual differences exist
in the pattern of glycemic control. The causes of
this variability are probably multifactorial and
include diet, physical activity, medical care, ac-
cess to medications, and medication adherence as
well as insulin secretion and resistance.10
Some studies have averaged HbA1c values over
the period of the study. We sought to expand on
this concept by using additional mathematical tech-
niques that take into consideration both the maxi-
mal value and extrapolated duration of abnormal
HbA1c measures, including slope and area under
and around the HbA1c versus time curve. Though
these strategies have their own inherent limitations
and assumptions (see Discussion), the intent of this
approach was to provide a more precise character-
ization of the pattern of glycemic control in the real
world of primary care practice and to assess the
relationship to change in estimated glomerular ﬁl-
tration rate (eGFR) and stage of CKD. To our
knowledge, this is the ﬁrst study in which these
measures of variation in HbA1c have been used to
examine the relationship between patterns of gly-
cemic control and diabetic complications. Speciﬁ-
cally, the purpose of this study was to examine the
relationship between ﬂuctuations in glycemic con-
trol (HbA1c) over time and changes in eGFR and
estimated stage of chronic kidney disease (CKD).
Methods
This retrospective cohort study examined adult pa-
tients (18 years of age) with a medical record–
established diagnosis of type 2 diabetes mellitus
who had been seen in one of the primary care
practices (ie, family medicine, internal medicine) at
an academic medical center in the southeastern
United States during the baseline time period 1998
to 2002. Follow-up visits through 2008 for those
patients with at least 5 measurements of glycemic
control (HbA1c) were evaluated. We chose 5
HbA1c values as a minimum number necessary to
characterize the slope and area under the curve
(AUC) measures (described in more detail, below).
All patients’ medical records were abstracted, and
data including demographic characteristics (age,
race, sex, insurance); duration of diabetes; height;
weight; blood pressure (BP); glycemic control
(HbA1c); and serum creatinine were collected. In-
formation about proteinuria was not consistently
available and was not included in this study. For
glycemic control, a HbA1c target value of 7%
was used, as recommended by the American Dia-
betes Association.10 The eGFRs at baseline and at
the most recent follow-up visit were calculated via
computer using the Modiﬁcation of Diet in Renal
Disease (MDRD) equation (eGFR  186  serum
creatinine [mg/dL](1.154)  age [years] (0.203) 
1.212 [if black]  0.742 [if female]). The MDRD
equation was chosen based on data by Rigalleau et
al11 demonstrating its utility in diabetic patients. In
addition, the eGFR values at baseline and at the
most recent follow-up were used to categorize each
participant’s stage of CKD based on the categori-
zation available from the National Kidney Founda-
tion: stage 1, 90 mL/min; stage 2, 60 to 89 mL/
min; stage 3, 30 to 59 mL/min; stage 4, 15 to 29
mL/min; stage 5, 15 mL/min or dialysis.12 Pat-
terns of glycemic control during the follow-up pe-
riod were characterized by computing the follow-
ing 10 measures from each patient’s HbA1c proﬁle:
Overall mean HbA1c
Change score (initial  ﬁnal HbA1c)
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Slope of trend line of HbA1c versus time
Proportion of HbA1c values above 7%
Area under the HbA1c versus time curve but
above the 7% threshold (see Figure 1)
Area between HbA1c versus time curve and the
7% threshold (area around threshold including area
both above and below the threshold; see Figure 1)
Area difference  area above 7% and below
HbA1c versus time curve minus area below 7% and
under the curve (see Figure 1)
SD of HbA1c values: SD  SQRT([1/{n-1}] 
[value-mean]2)
Root mean square of HbA1c values around 7%:
rms  SQRT([1/n]  [value  7]2)
Average excess of HbA1c values above 7%, av-
eraged over all values exceeding 7%
Examples of the measures involving area under
the HbA1c versus time curve that were calculated
for each patient are graphically depicted in Figure
1. Correlations among the HbA1c proﬁle measures
and between the HbA1c proﬁle measures and the
demographic/clinical variables were examined.
Stepwise linear regression modeling was then used to
examine (1) the contribution of the demographic/
clinical variables to predicting the change in eGFR
from baseline to ﬁnal measurement, (2) the contri-
bution of the HbA1c proﬁle measures to predicting
the change in eGFR from baseline to ﬁnal mea-
surement, and (3) the additional contribution of
HbA1c measures while controlling for signiﬁcant
independent variables among demographic charac-
teristics (age, race, sex) and clinical measures (du-
ration of diabetes, BP, use of an angiotensin-con-
verting enzyme inhibitor (ACEI) or angiotensin
receptor blocker (ARB), initial eGFR, initial
HbA1c, and number of HbA1c values). Logistic
regression modeling was used to examine the con-
tribution of these measures to predicting an in-
crease of one or more CKD stages from baseline to
ﬁnal measurement while controlling for the same
independent variables. The analysis was conducted
using SAS software version 9.2 (SAS Institute,
Cary, NC). Model parameters and 95% CIs are
reported.
Results
From a population of 2155 patients with diabetes
who had at least one visit during the enrollment
time period, a total of 791 patients who had at least
5 HbA1c values over the follow-up period were
included in the study. Mean age was 54  8 years;
68% were women and 75% were African American.
Baseline BP, HbA1c, and eGFR values and the
percentage of use of ACEIs or ARBs by race and
sex are given in Table 1, which also shows sum-
mary statistics for HbA1c decrease, eGFR de-
crease, and increasing stage of CKD. Mean fol-
low-up was 7.6  1.9 years; mean number of
years from ﬁrst to last HbA1c measurement was
6.78  2.0 years; mean number of total primary
Figure 1. Examples of measures for patterns of
fluctuation in glycosylated hemoglobin levels. Area
under the curve for glycosylated hemoglobin versus
time above 7% (top), approximately 7% (center), and
the area difference (bottom).
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care visits was 57.96  33.14 visits; mean number
of serum creatinine measurements was 14  9.7
measurements; and mean number of HbA1c mea-
surements was 29.4  7.2 measurements. Over-
all, there was a similar pattern of decline in eGFR
from baseline to the end of follow-up, with Af-
rican Americans of both sexes having a greater
and more rapid decline (mean decline in eGFR,
12.0 mL/min/1.73 m2 for African-American men
vs 6.4 mL/min/1.73 m2 for white men; P  .12;
mean decline in eGFR, 14.5 mL/min/1.73 m2 for
African-American women vs 6.5 mL/min/1.73
m2 for white women; P  .01) than that observed
among white patients (see Figure 2).
Correlation Analysis
The 10 HbA1c proﬁle measures of glycemic con-
trol variability were highly correlated with one an-
other. The highest intercorrelations (exceeding
0.9) were AUC above 7%, with AUC approxi-
mately 7% (r  0.98), AUC difference (r  0.98),
and HbA1c mean (r  0.91), as well as AUC dif-
Table 1. Mean Baseline and Change Statistics by Race and Sex
Sex Race n Variable* Mean (SD)
Female African American 433 Baseline SBP 135.2 (20.3)
Baseline DBP 80.4 (11.3)
Baseline HbA1c 8.8 (2.3)
Baseline eGFR 100.6 (30.7)
Taking ACEIs/ARBs (%) 47.6
HbA1c decrease 0.70 (2.42)
eGFR decrease overall 14.5 (30.9)
Mean eGFR decrease/year 1.9 (4.2)
% worse CKD stage 38.8
White 102 Baseline SBP 129.5 (18.0)
Baseline DBP 75.6 (11.0)
Baseline HbA1c 7.5 (1.9)
Baseline eGFR 85.5 (25.3)
Taking ACEIs/ARBs (%) 47.1
HbA1c decrease 0.50 (2.10)
eGFR decrease overall 6.5 (25.1)
Mean eGFR decrease/year 0.9 (3.6)
% worse CKD stage 35.0
Male African American 162 Baseline SBP 133.2 (20.4)
Baseline DBP 80.1 (12.1)
Baseline HbA1c 8.9 (2.5)
Baseline eGFR 95.0 (25.9)
Taking ACEIs/ARBs (%) 50.3
HbA1c decrease 0.96 (3.15)
eGFR decrease overall 12.0 (32.7)
Mean eGFR decrease/year 1.8 (4.6)
% worse CKD stage 36.9
White 94 Baseline SBP 128.8 (17.1)
Baseline DBP 76.1 (11.4)
Baseline HbA1c 8.1 (1.9)
Baseline eGFR 91.5 (24.7)
Taking ACEIs/ARBs (%) 43.0
HbA1c decrease 0.95 (2.23)
eGFR decrease overall 6.4 (24.8)
Mean eGFR decrease/year 1.0 (3.8)
% worse CKD stage 29.0
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosolated hemoglobin; eGFR, estimated glomerular ﬁltration
rate; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CKD, chronic kidney disease.
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ference with HbA1c mean (r  0.94) and AUC
approximately 7% (r  0.92).
Six of the correlations between HbA1c proﬁle
measures and demographic/clinical variables ex-
ceeded 0.5, and all of these involved the baseline
HbA1c value. Baseline HbA1c was correlated with
HbA1c decrease (r  0.65), HbA1c mean (r 
0.58), average HbA1c excess above 7% (r  0.57),
HbA1c root mean square approximately 7% (r 
0.56), AUC difference (r  0.52), and AUC above
7% (r  0.51) (all P  .01).
Decrease in eGFR was correlated with duration
of diabetes (r  0.18; P  .01) and with the 3 area
measures: AUC above HbA1c value of 7% (r 
0.16; P  .01); AUC around HbA1c value of 7%
(r  0.16; P  .01); and the area difference (r 
0.15; P  .01).
Linear Regression Modeling
Collectively, the 11 demographic/clinical variables
explained 27.9% of the variation in eGFR decrease.
Among these, the signiﬁcant independent predic-
tors of change in eGFR were age, mean SBP, initial
HbA1c, initial eGFR, and number of HbA1c values
(all P .01), but not race and sex. These 5 variables
explained 27.3% of the variation in eGFR decrease.
By contrast, the HbA1c proﬁle measures ex-
plained only 4.9% of the variation in eGFR de-
crease. To minimize confounding associated with
multicollinearity, the AUC difference was omitted
from the model because it was the least highly
correlated with eGFR decrease. Those remaining
HbA1c proﬁle measures that made signiﬁcant in-
dependent contributions in this revised model were
AUC above 7%, AUC approximately 7%, HbA1c
decrease, HbA1c SD, and HbA1c root mean square
of approximately 7%; collectively these 5 measures
explained 4.5% of the variation in eGFR decrease.
To determine whether the HbA1c proﬁle mea-
sures provided additional explanatory value beyond
that provided by the signiﬁcant demographic/clin-
ical variables, a conditional stepwise regression
analysis was conducted. The 5 signiﬁcant demo-
graphic/clinical variables were forced into the
model, whereas each HbA1c proﬁle measure was
added subsequently in stepwise fashion into the
model. While controlling for the demographic/
clinical variables, among all measures characteriz-
ing glycemic control, the strongest predictor of
change in eGFR was the proportion of HbA1c
values exceeding 7% (P  .02). This stepwise ad-
dition increased the model R2 from 27.3% to
27.9%, representing an improvement of only 2.2%
in explaining variance. Regression model parame-
ter estimates and conﬁdence limits are shown in
Table 2.
Figure 2. Decline in mean estimated glomerular
filtration rate (GFR) by race and sex, 1998 to 2008.
Table 2. Linear Regression Model of Significant Predictors of Change in Estimated Glomerular Filtration Rate
Explanatory Variable Fitted Coefﬁcient 95% Conﬁdence Limits
Age 0.40 0.15, 0.66
Baseline HbA1c 1.63 0.73, 2.53
Baseline estimated glomerular ﬁltration rate 0.47 0.40, 0.54
HbA1c readings (n) 0.81 1.08, 0.55
Mean systolic blood pressure 0.47 0.32, 0.62
Proportion of HbA1c readings 7% 8.15 13.64, 2.66
HbA1c, glycosolated hemoglobin.
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Logistic Regression Modeling
For the logistic regression model, among demo-
graphic and clinical variables, age, mean SBP, and
duration of diabetes (all P  .05) were the only
signiﬁcant predictors of worsening by one or more
stage of CKD. While controlling for these vari-
ables, among all measures characterizing glycemic
control, only 2 variables, namely the change in
HbA1c (baseline minus ﬁnal; P  .01) and the
average excess of HbA1c above 7% (P  .01) pro-
vided signiﬁcant additional explanatory power. Us-
ing the change in HbA1c from baseline to follow-
up, we found that, for each 1-unit change in
HbA1c, the odds of seeing a worsening in CKD
stage increased by 8%. Furthermore, for each
1-unit increase in the average excess in HbA1c
above 7%, the odds of seeing a worsening in CKD
stage increased by about 18%. The odds ratios and
conﬁdence limits are given in Table 3.
Discussion
We used a novel approach to explore the associa-
tion of patterns of HbA1c ﬂuctuation with changes
in eGFR and stage of CKD using medical record
data from a population of diabetic patients seen in
a primary care setting between 1998 and 2008. We
demonstrated that the measureable effect of HbA1c
ﬂuctuations on progression of CKD over the study
period, beyond the impact of routine demographic
and clinical variables, was limited. This real-world
observational study differs from controlled clinical
trials in that our population, which was receiving
routine primary care, demonstrated considerable
ﬂuctuations in HbA1c control relative to that ob-
served in controlled clinical trials that study a more
carefully selected group. Contrary to our expecta-
tion, these additional techniques only contributed
modestly to our understanding of the relationship
between glycemic control and change in eGFR
and/or stage of kidney disease and were not supe-
rior to the simple baseline to ﬁnal change in
HbA1c.
Overall, study participants had only a modest
decline in eGFR, consistent with expectations for
our study population, which had a slightly younger
mean age, a more limited duration of diabetes, and
a signiﬁcant percentage of patients who were being
treated with ACEI/ARBs than the populations of
some published trials. Our ﬁndings are consistent
with previous literature in that we demonstrate that
BP elevation, duration of diabetes, and age remain
important predictors of change in eGFR.13–18 The
identiﬁcation of BP as a predictor of change in
eGFR among our patients is important in that
microvascular beneﬁts from tight control of hyper-
tension in patients with type 2 diabetes have been
demonstrated after only 3 years of treatment, well
within the 7.6-year median follow-up of patients in
this study.14 Furthermore, a sustained reduction in
blood pressure may be the single most important
intervention in reducing the progression of CKD
in patients with type 1 and type 2 diabetes.16 Our
data reinforces the relationship between BP control
and eGFR in these primary care patients.
Importantly, we also demonstrated a greater de-
cline in eGFR among African Americans than that
observed among whites, emphasizing the impor-
tance of this racial disparity. In our study, mean
baseline systolic and diastolic BP as well as mean
baseline HbA1c were higher in African Americans
of both sexes, which may have contributed to the
racial differences observed at follow-up. This sug-
gests the need for additional tailored population-
level strategies designed to improve risk factor
management among African Americans with diabe-
tes, as has been recommended in the National Kid-
ney Foundation’s clinical practice recommenda-
tions.17
The key ﬁnding of our work is that 5 variables,
namely age, mean SBP, initial HbA1c, initial
eGFR, and number of HbA1c values (all P  .01)
explained 27.3% of the variation in change in
eGFR; adding additional measures regarding
HbA1c ﬂuctuations explained an additional 2.2%
to 4.5% of the variation in eGFR decrease. Al-
though their contribution to predicting changes in
eGFR and worsening of CKD stage were less than
the more established variables (eg, BP, duration of
Table 3. Logistic Regression Model of Significant
Predictors of Worsening by One or More Chronic
Kidney Disease Stages
Explanatory Variable
Odds Ratio
(95% Conﬁdence Limits)
Age 1.037 (1.009, 1.056)
Duration of diabetes in years 1.164 (1.061, 1.276)
Mean systolic blood pressure 1.026 (1.012, 1.039)
HbA1c decrease 1.083 (1.017, 1.154)
Average excess of HbA1c 7% 1.173 (1.031, 1.335)
HbA1c, glycosolated hemoglobin.
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diabetes, age), the changes in these glycemic con-
trol pattern variables were at signiﬁcant or near-
signiﬁcant levels and represent a contribution to
our understanding.
This suggests that these strategies for estimat-
ing the pattern of ﬂuctuations in glycemic con-
trol over time in primary care settings contribute
only modestly to explaining the variance in
change in eGFR and stage of CKD. This out-
come has important implications. Clinicians of-
ten respond to ﬂuctuations in HbA1c as indepen-
dent events based on the understanding that
tighter glycemic control will lead to greater re-
duction in the risk for microvascular complica-
tions. However, our ﬁndings and those of the
recent re-analysis of the DCCT trial,9 while em-
phasizing the importance of HbA1c, suggest that
small ﬂuctuations in the pattern of HbA1c over
time may be less important than the maximal
change in HbA1c achieved with treatment. The
concept of metabolic memory as suggested from
the Epidemiology of Diabetes Interventions and
Complications follow-up of DCCT partici-
pants,4 in which substantial reductions in HbA1c
early on in the intensively treated group had
long-lasting implications for reducing the risk of
future microvascular complications, is consistent
with this observation. Although speculative, this
may imply that the pathophysiologic steps lead-
ing to microvascular complications such as CKD
may not be associated with glycemic control (as
measured by HbA1c) in a continuous fashion but
perhaps through mechanisms that are more
threshold driven and/or time dependent.
Though the contribution of HbA1c is signiﬁ-
cant, our ﬁndings underscore the importance of not
considering HbA1c independently but rather in the
context of other risk factors for CKD including BP,
race, and age/duration of diabetes. Although the
pattern of glycemic control contributed only mod-
estly, and age, duration of diabetes, BP, and similar
factors were independently predictive in the models
studied, they collectively explained only 30% of
the variance in eGFR change. It is clear from this
and other studies that other less well-described
factors seem to explain the greatest variation in the
risk of worsening eGFR. Active research programs
are currently underway to identify new risk factors
that may be more strongly and consistently linked
to CKD.18
Treatment with ACEIs or ARBs of diabetic pa-
tients with conﬁrmed microalbuminuria or pro-
teinuria, even in the absence of hypertension, has
been shown to slow progression of CKD.16,19 In
our study, treatment with ACEIs/ARBs was not an
independent predictor of change in eGFR or
change in CKD stage, in part because the vast
majority of patients were receiving these medica-
tions and this study was not designed to examine
that question.
This study has a number of limitations. As-
sumptions inherent in extrapolating HbA1c data
from a single time point to a longer time period;
the lack of measurement of HbA1c at similar
time points among all participants; the lack of
available data on other important risk factors
such as microalbuminuria/proteinuria, diet, and
medication adherence; and the observational na-
ture of the study in routine primary care practice
limit the interpretation of these results. Measure-
ment of serum creatinine has a 10% measure-
ment error, which is not corrected by the MDRD
equation. Likewise, the MDRD equation may be
less precise as an estimate of GFR in patients
with relatively preserved renal function. How-
ever, given the profound discussions in the liter-
ature in recent years about the importance of
tight glycemic control, we contend that addi-
tional research is needed to better understand
potential associations between the magnitude,
frequency, and overall time course of ﬂuctuations
in HbA1c in routine primary care and the devel-
opment of CKD and other microvascular com-
plications of diabetes. Additional studies using
these or comparable measures to assess patterns
of glycemic control in observational studies using
primary care patients are needed to determine
the validity and reproducibility of this approach.
Perhaps the use of one or more of these 10
techniques to better characterize the pattern of
glycemic control in large-scale, long-term clini-
cal trials, in which HbA1c measures are routinely
obtained at similar and precise intervals, might
result in an improved understanding of the rela-
tionship with eGFR or other diabetes-speciﬁc
outcome measures above and beyond those avail-
able from conventional analytical techniques.
Conclusion
These data suggest that traditional demographic
and clinical risk factors remain importantly associ-
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ated with changes in eGFR and that ﬂuctuations in
glycemic control, though important and in need of
further investigation, should be evaluated in the
context of the patient’s overall risk proﬁle.
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